Virol J . Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis

[tetano]

Virol J


. 2021 Jul 27;18(1):157.
doi: 10.1186/s12985-021-01604-1.
Association of dyslipidemia with the severity and mortality of coronavirus disease 2019 (COVID-19): a meta-analysis


Yanli Liu ¹ , Yilong Pan ¹ , Yuyao Yin ¹ , Wenhao Chen ¹ , Xiaodong Li ²



Affiliations

• PMID: 34315474
• DOI: 10.1186/s12985-021-01604-1

Abstract

Background: The numbers of confirmed cases of coronavirus disease 2019 (COVID-19) and COVID-19 related deaths are still increasing, so it is very important to determine the risk factors of COVID-19. Dyslipidemia is a common complication in patients with COVID-19, but the association of dyslipidemia with the severity and mortality of COVID-19 is still unclear. The aim of this study is to analyze the potential association of dyslipidemia with the severity and mortality of COVID-19.
Methods: We searched the PubMed, Embase, MEDLINE, and Cochrane Library databases for all relevant studies up to August 24, 2020. All the articles published were retrieved without language restriction. All analysis was performed using Stata 13.1 software and Mantel-Haenszel formula with fixed effects models was used to compare the differences between studies. The Newcastle Ottawa scale was used to assess the quality of the included studies.
Results: Twenty-eight studies involving 12,995 COVID-19 patients were included in the meta-analysis, which was consisted of 26 cohort studies and 2 case-control studies. Dyslipidemia was associated with the severity of COVID-19 (odds ratio [OR] = 1.27, 95% confidence interval [CI] 1.11-1.44, P = 0.038, I² = 39.8%). Further, patients with dyslipidemia had a 2.13-fold increased risk of death compared to patients without dyslipidemia (95% CI 1.84-2.47, P = 0.001, I² = 66.4%).
Conclusions: The results proved that dyslipidemia is associated with increased severity and mortality of COVID-19. Therefore, we should monitor blood lipids and administer active treatments in COVID-19 patients with dyslipidemia to reduce the severity and mortality.

Keywords: COVID-19; Dyslipidemia; Mortality; SARS-CoV-2; Severity.